{"id":693143,"date":"2026-08-04T03:24:36","date_gmt":"2026-08-04T03:24:36","guid":{"rendered":"https:\/\/www.europesays.com\/es\/693143\/"},"modified":"2026-08-04T03:24:36","modified_gmt":"2026-08-04T03:24:36","slug":"los-nuevos-farmacos-adelgazantes-semaglutida-tirzepatida-y-el-reto-de-su-regulacion","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/es\/693143\/","title":{"rendered":"Los nuevos f\u00e1rmacos adelgazantes: semaglutida, tirzepatida y el reto de su regulaci\u00f3n"},"content":{"rendered":"<p>En pocos a\u00f1os, medicamentos como<strong> semaglutida (Ozempic\u00ae y Wegovy\u00ae) o tirzepatida (Mounjaro\u00ae)<\/strong> han pasado de ser tratamientos para la diabetes y la obesidad a convertirse en un aut\u00e9ntico fen\u00f3meno social. Han ocupado portadas, protagonizado debates en redes sociales e incluso modificado la percepci\u00f3n colectiva sobre el tratamiento del exceso de peso.<\/p>\n<p>Sin embargo, junto con su enorme impacto sanitario, han surgido importantes interrogantes jur\u00eddicos y regulatorios. Nos encontramos ante un claro ejemplo de <strong>c\u00f3mo la innovaci\u00f3n biom\u00e9dica puede avanzar a una velocidad superior a la capacidad de adaptaci\u00f3n de las normas.<\/strong><\/p>\n<p><a id=\"ads3\" href=\"https:\/\/global.economistjurist.es\/global-ia-juridica\/landing\/?utm_source=robalectura-EJ\" target=\"_blank\" rel=\"nofollow noopener\"><img decoding=\"async\" style=\"text-align: center;  margin: auto; margin-bottom: 0px;max-width: 600px; width:100%;\" class=\"\" alt=\"Global IA\" src=\"https:\/\/global.economistjurist.es\/imgrev\/gi800x500.jpg\" bad-src=\"https:\/\/global.economistjurist.es\/imgrev\/gi800x500.jpg\"\/><\/a><\/p>\n<p>Uno de los cambios m\u00e1s relevantes de los \u00faltimos a\u00f1os ha sido el reconocimiento progresivo de la obesidad como una enfermedad cr\u00f3nica, compleja y multifactorial. Este cambio de paradigma explica el creciente inter\u00e9s por tratamientos farmacol\u00f3gicos <strong>capaces de lograr p\u00e9rdidas de peso mantenidas y cl\u00ednicamente relevantes<\/strong>.<\/p>\n<p>&#8230;<\/p>\n<p style=\"font-size:2.2rem;margin-bottom:10px;color:#003454;text-align:center;\">\n  Suscr\u00edbete a nuestra<br \/>\n    NEWSLETTER<\/p>\n<p>    <img decoding=\"async\" src=\"https:\/\/www.europesays.com\/es\/wp-content\/uploads\/2026\/08\/ej12.png\" alt=\"logo-EJ\" style=\"width: 35px;border: 5px solid #fff;margin-top: -20px;background-color: #fff\"\/><br \/>\n    CONTENIDO EXCLUSIVO PARA SUSCRIPTORES<\/p>\n<p>    <a href=\"https:\/\/global.economistjurist.es\/global-ia-juridica\/landing\/?utm_source=EJ_Premium#div-solicitud\" target=\"_blank\" style=\"display: block;text-decoration: none\" rel=\"nofollow noopener\">&#13;<\/p>\n<p>            <img decoding=\"async\" src=\"https:\/\/www.europesays.com\/es\/wp-content\/uploads\/2026\/08\/globai-ia-formularios.jpg\" alt=\"Banner Colaboraci\u00f3n\" style=\"display: block;width: 100%;height: auto;border-radius: 10px;object-fit: cover\"\/><br \/>\n        &#13;<br \/>\n        &#13;<br \/>\n    <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"En pocos a\u00f1os, medicamentos como semaglutida (Ozempic\u00ae y Wegovy\u00ae) o tirzepatida (Mounjaro\u00ae) han pasado de ser tratamientos para&hellip;\n","protected":false},"author":2,"featured_media":693144,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[92],"tags":[70177,125326,25,24,56658,165,117591,5693,8799,125325,166,27247,23,68290,8798],"class_list":["post-693143","post","type-post","status-publish","format-standard","has-post-thumbnail","category-salud","tag-aemps","tag-derecho-sanitario","tag-es","tag-espana","tag-farmacos-adelgazantes","tag-health","tag-mounjaro","tag-obesidad","tag-ozempic","tag-regulacion-farmaceutica","tag-salud","tag-semaglutida","tag-spain","tag-tirzepatida","tag-wegovy"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@es\/117035104424222910","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/posts\/693143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/comments?post=693143"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/posts\/693143\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/media\/693144"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/media?parent=693143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/categories?post=693143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/es\/wp-json\/wp\/v2\/tags?post=693143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}